New advances in the treatment of chronic rhinosinusitis with nasal polyps from pathophysiology to biologic targeted therapy.

What was studied

This paper looked at a long-term sinus disease with nasal polyps. The authors call it CRSwNP. The abstract says type 2 inflammation mainly drives it. Usual care does not fix the immune problem underneath. So the polyps often come back after surgery. The authors did a narrative review of key papers. They looked at how the disease works and at biologic drugs.

What they found

The review looked at dupilumab, mepolizumab, omalizumab and tezepelumab. Each drug blocks a key molecule in type 2 inflammation. The abstract says they gave good and lasting control of the disease. They made the polyps smaller and eased nose symptoms. They also helped the sense of smell. People needed fewer steroid pills and fewer repeat surgeries. The drugs also helped asthma in people who had both diseases.

What it means for patients

The authors see these drugs as a big step in treating CRSwNP. Care may move from easing symptoms to a plan for each person. That plan would rest on the type of disease, other illnesses, and goals. One such goal is to put the disease into remission. The authors offer a framework for using these drugs with care.

Why it is not certain yet

This was a narrative review, not a new study. The abstract does not give numbers of studies or people. A review can only be as good as the studies in it. The authors say more work is needed on markers that predict response. Studies that compare the drugs directly are also needed. New targets for disease not driven by type 2 inflammation need study too.

Source

New advances in the treatment of chronic rhinosinusitis with nasal polyps from pathophysiology to biologic targeted therapy.

We restate facts from the source record in our own words. The original wording belongs to its publisher.